Identification |
Name: | Bortezomib |
Synonyms: | Pyz-Phe-boroLeu;Boronic acid, [(1(R)-3-methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]-;Boronic acid, [1-[[1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl) amino]propyl]amino]-3-methylbutyl]-, L-(S)-;[(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid;PS 341 (pharmaceutical); |
CAS: | 179324-69-7 |
Molecular Formula: | C19H25BN4O4 |
Molecular Weight: | 384.24 |
InChI: | InChI=1/C19H25BN4O4/c1-13(2)10-17(20(27)28)24-18(25)15(11-14-6-4-3-5-7-14)23-19(26)16-12-21-8-9-22-16/h3-9,12-13,15,17,27-28H,10-11H2,1-2H3,(H,23,26)(H,24,25)/t15-,17-/m1/s1 |
Molecular Structure: |
|
Properties |
Density: | 1.214 |
Refractive index: | 1.564 |
Solubility: | In water, 3.3 to 3.8 mg/mL in a pH range of 2 to 6.5 (as the monomeric boronic acid) In water, 76 mg/L at 25 deg C (est) |
Appearance: | yellow solid |
Specification: |
?Bortezomib (CAS NO.179324-69-7), its Synonyms are ((1R)-3-Methyl-1-(((2S)-3-phenyl-2-((pyrazinylcarbonyl)amino)propanoyl)amino)butyl)boronic acid ; Boronic acid, ((1R)-3-methyl-1-(((2S)-1-oxo-3-phenyl-2-((pyrazinylcarbonyl)amino)propyl)amino)butyl)- ; N-((1S)-1-Benzyl-2-(((1R)-1-(dihydroxyboranyl)-3-methylbutyl)amino)-2-oxoethyl)pyrazinecarboxamide ; Velcade . It is yellow solid.
|
Color: | Powder |
Usage: | It is used as a medicine to treat some refractory disease, for example relapsed multiple myeloma and mantle cell lymphoma. |
Safety Data |
|
|